Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP
Johns Hopkins Kimmel Cancer Center

Posted: 7/16/2018
Expires: 7/16/2019
Estimated time to complete: 1 hour

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Instructions for Earning CE credit

This activity has expired, credit is no longer available.


Quick Tips

What are the latest data on newly approved agents for primary, relapsed, and refractory follicular lymphoma?
How do I incorporate emerging therapies into treatment plans for patients with CLL?
What are the best strategies for managing the side effects of medications for follicular lymphoma?
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.